Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases

NCT05012254 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT05012254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05012254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 18, 2021
Completion date
December 15, 2027
Enrollment
71 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, adult, lung cancer, non small cell lung cancer